A
Anne Munck
Researcher at University of Paris
Publications - 111
Citations - 7066
Anne Munck is an academic researcher from University of Paris. The author has contributed to research in topics: Cystic fibrosis & Ivacaftor. The author has an hindex of 35, co-authored 107 publications receiving 5934 citations. Previous affiliations of Anne Munck include Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Jennifer L. Taylor-Cousar,Anne Munck,Edward F. McKone,Cornelis K. van der Ent,Alexander Moeller,Christopher Simard,Linda T Wang,Edward P. Ingenito,Charlotte M. McKee,Yimeng Lu,J Lekstrom-Himes,J. Stuart Elborn +11 more
TL;DR: These data show that lumacaftor in combination with ivacaftors provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.
Journal ArticleDOI
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Jane C. Davies,Jane C. Davies,Claire E. Wainwright,Gerard J. Canny,Mark A. Chilvers,Michelle S. Howenstine,Anne Munck,Jochen G. Mainz,Sally Rodriguez,Haihong Li,Karl Yen,Claudia L. Ordoñez,Richard C. Ahrens +12 more
TL;DR: In patients who are younger and healthier than those in previously studied populations, ivacaftor demonstrated a significant improvement in pulmonary function, weight, and CFTR activity compared with placebo.
Journal ArticleDOI
ECFS best practice guidelines: the 2018 revision
Carlo Castellani,Alistair J.A. Duff,Alistair J.A. Duff,Scott C. Bell,Harry G.M. Heijerman,Anne Munck,Felix Ratjen,Isabelle Sermet-Gaudelus,Kevin W Southern,Jürg Barben,Patrick A. Flume,Pavla Hodková,Nataliya Kashirskaya,Maya Kirszenbaum,Sue Madge,H. Oxley,Barry J. Plant,Sarah Jane Schwarzenberg,Alan R. Smyth,Giovanni Taccetti,Thomas O. F. Wagner,Susan P. Wolfe,Pavel Drevinek +22 more
TL;DR: A broad overview of the standards expected for newborn screening, diagnosis, preventative treatment of lung disease, nutrition, complications, transplant/end of life care and psychological support in key aspects of CF care, in the context of a fast-moving and dynamic field is given.
Journal ArticleDOI
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines
Alan R. Smyth,Scott C. Bell,Snezana Bojcin,Mandy Bryon,Alistair J.A. Duff,Patrick A. Flume,Nataliya Kashirskaya,Anne Munck,Felix Ratjen,Sarah Jane Schwarzenberg,Isabelle Sermet-Gaudelus,Isabelle Sermet-Gaudelus,Kevin W Southern,Giovanni Taccetti,Gerald Ullrich,Sue Wolfe +15 more
TL;DR: The objective of the document is to give a broad overview of the standards expected for screening, diagnosis, pre-emptive treatment of lung disease, nutrition, complications, transplant/end of life care and psychological support.
Journal ArticleDOI
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
Kris De Boeck,Anne Munck,Seth Walker,Albert Faro,Peter Hiatt,Geoffrey Gilmartin,Mark Higgins +6 more
TL;DR: Ivacaftor was efficacious in a group of patients with CF who had selected non-G551D gating mutations and was generally well tolerated.